Related Experiment Video

Updated: Jun 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pleiotropic effects of statins in atherosclerotic disease

Gerard Pasterkamp1, Guus W van Lammeren

  • 1Laboratory of Experimental Cardiology, University Medical Centre Utrecht, 3584CX Utrecht, The Netherlands. g.pasterkamp@umcutrecht.nl

Expert Review of Cardiovascular Therapy
|September 11, 2010
PubMed

Insights

Statins reduce cardiovascular events by lowering LDL cholesterol. However, their impact on atherosclerotic plaque inflammation and composition, whether from lipid-lowering or pleiotropic effects, requires further investigation.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Pathophysiology

Background:

  • Statins are primary treatments for hypercholesterolemia and atherosclerotic disease, reducing cardiovascular events, morbidity, and mortality.
  • The precise mechanisms by which statins affect inflammatory responses and atherosclerotic plaque morphology in humans are debated.
  • It remains unclear if statin-induced plaque changes are due to low-density lipoprotein (LDL) reduction or anti-inflammatory pleiotropic effects.

Discussion:

  • This content discusses a study by Puato et al. examining atorvastatin's effects on plaque morphology.
  • The study compared two different atorvastatin dosages against a non-statin lipid-lowering drug.
  • The research aims to differentiate the effects of LDL lowering from potential pleiotropic actions.

Key Insights:

  • Statins significantly impact cardiovascular health by managing hypercholesterolemia.
  • Atherosclerotic plaque composition and inflammatory markers are key areas of investigation for statin efficacy.
  • Distinguishing between LDL-lowering and pleiotropic effects is crucial for understanding statin's full therapeutic potential.

Outlook:

  • Further research is needed to elucidate the non-lipid-lowering effects of statins on atherosclerotic plaques.
  • Understanding these mechanisms could lead to optimized therapeutic strategies for cardiovascular disease.
  • Comparative studies with different lipid-lowering agents will refine treatment protocols.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...